We use cookies for a better user experience. Read our Privacy Policy

I Agree

Companion Diagnostics Market

Companion Diagnostics Market (Indication: Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Companion Diagnostics Market Outlook 2028

  • The global companion diagnostics market was valued at US$ 5.24 Bn in 2020
  • It is estimated to expand at a CAGR of 9% from 2021 to 2028
  • The global companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2028

Analysts’ Viewpoint on Companion Diagnostics Market Scenario

The global companion diagnostics market is expected to witness tremendous growth opportunities due to rising incidences of oncology and chronic disorders across the globe. Several companion diagnostics market players are leveraging lucrative revenue opportunities. Companion diagnostics are used to identify the response of oncology patients to the targeted drug therapy. This helps in developing personalized medicine for cancer patients. However, the lengthy and complicated approval process and the equally prolonged time to develop companion diagnostics are impacting the growth of the global companion diagnostics market. Furthermore, the unavailability of reimbursement policies in some regions is also projected to hamper market growth.

COVID-19 Impact on Global Companion Diagnostics Market

The coronavirus pandemic has put intense pressure on the global healthcare system. With shortage of hospital beds, medical staff, and necessary protective equipment required for elective surgical processes, healthcare practitioners gave priority to critical patients suffering from severe health complications. Considering risk and safety of patients, non-emergency diagnostic and treatment procedures have been cancelled or postponed in the time of rapidly spreading coronavirus. This factor has negatively affected the global companion diagnostics market as cancer surgeries also been cancelled. Clinical trials in oncology have also been affected by the coronavirus. However, the market is booming after the significant efforts taken by governments, healthcare practitioners, and market stakeholders to recover from losses caused due to pandemic.

Request a sample to get extensive insights into the Companion Diagnostics Market

Increasing Prevalence of Chronic Disorders Fueling Market Growth

Rising incidences of HIV, thalassemia, colorectal cancer, melanoma, breast cancer, gastric cancer, and lung cancer is driving the demand for companion diagnostics procedures. There is a growing demand for companion diagnostic tests for early detection and screening of chronic diseases. These tests also help reduce the side effects of drugs, improve patient outcomes, provide high diagnostic accuracy and specificity, reduce pharmacotherapy variability, and identify the most effective targeted therapy options. They are also associated with higher drug development success. The global companion diagnostics market is booming due to the increasing demand for personalized medicines. Rising incidences of cancer and reduction in cost of developing drugs are also having a positive impact on the global companion diagnostics market. Companion diagnostics tests and procedures help bring about better decisions with respect to treatment.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Rising Awareness of Breast Cancer Globally

Growing incidences of breast cancer across the globe is one of the key factors accelerating the global companion diagnostics market, thereby creating value-grab opportunities for market contributors. Increasing awareness of breast cancer and focus of health practitioners on its treatment is accelerating the global companion diagnostics market growth. However, the lung cancer segment is also generating substantial revenues in the global companion diagnostics market. Rising pollution, unhealthy food, smoking, and chewing tobacco are mainly responsible for lung cancer, which results in the maximum number of deaths worldwide. It is particularly prevalent in low-income nations. This, alongside the development of numerous companion diagnostics and biomarkers for lung cancer is mainly boosting market growth. Companion diagnostics enable healthcare professionals to understand the side effects and potential risks posed by a particular therapeutic product. This eventually helps in fine tuning treatment procedures.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Companion Diagnostics Market

North America to Lead Companion Diagnostics Market

North America is expected to account for a major market share of the global companion diagnostics market. Rising affordability of treatment and well-established healthcare infrastructure are driving the companion diagnostics market in the region. The increasing prevalence of chronic diseases all over the world demand companion diagnostics procedures. A large number of ongoing clinical trials, outsourcing services, research activities, and increasing healthcare investment by governments are some of the factors responsible for the growth of the companion diagnostics market in North America. Moreover, the significant presence of manufacturers is fueling the expansion of the North America companion diagnostics market. Asia Pacific and Latin America are other attractive companion diagnostics regions, where the market is poised to increase due to rising healthcare spending and improving healthcare facilities.

Companion Diagnostics Market: Overview

  • Companion diagnostics are biological tests or assays, which aid in predicting the clinical effectiveness or safety of the therapeutic intervention administered to diseased individuals. These diagnostic tests assist physicians in taking effective treatment decisions by elucidating the efficacy of a specific drug prescribed for a specific target population. For instance, Herceptin (trastuzumab), a monoclonal antibody treatment prescribed for treating breast cancer patients who contain one or more copies of the HER2 gene.
  • Companion diagnostics hold significant growth potential in the near future, owing to several tests in pipeline. The major advantage associated with the use of companion diagnostics is that it aids in predicting whether a patient will respond to a particular therapy and improves patient outcomes, thereby reducing the overall healthcare costs. Other advantages include the ruling out of generic therapies, thereby preventing side effects and resultant hospitalizations.

Companion Diagnostics Market: Key Drivers

  • Technological advancements, higher prevalence of cancer across the globe, research & development activities, drug development, demand for personalized medicines, expansion of the pharmaceutical industry, key mergers & acquisitions, and impact of COVID-19 on companion diagnostics are projected to boost the growth of the global market during the forecast period. Rise in prevalence and incidence of various infectious diseases such as HIV would attract advanced companion diagnostics, which is likely to propel the global companion diagnostics market during the forecast period. Breast cancer affects one in eight women in their lifetime, and the number of breast cancer cases is rising consistently both in developing and developed countries. According to a research, breast cancer is considered the most prevalent cancer in the U.S. According to Breast Cancer Statistics, 287,850 breast cancer cases are expected to be diagnosed in women in 2022. This is likely to augment the global market.
  • Major risk factors for cancer are heredity, aging, obesity, high alcohol consumption, hormone replacement therapy, and cosmetic implants. Technological advancements leading to fast approval of companion diagnostic tests/assays are projected to drive the global market in the next few years. According to research, in 2020, around 44 CDx assays were approved by the FDA. Hence, regulatory approvals for CDx assays across countries is anticipated to propel the global market during the forecast period.

Market Segmentation: Companion Diagnostics Market

  • In terms of indication, the global companion diagnostics market has been classified into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others (HIV and thalassemia)
  • The breast cancer segment accounted for the largest market share in 2020 and the trend is expected to continue during the forecast period. Rise in prevalence of breast cancer among middle-aged women across the globe and surge in awareness about the early diagnosis of breast cancer are likely to augment the segment in the next few years. Prostate, lung, and colorectal cancer are the most common cancers diagnosed in men and accounted for 40% of the cases. In women, breast, lung, and colorectal cancer account for more than 50% of the cancer cases.
  • In 2020, around 2.3 million women were diagnosed with breast cancer, and 685,000 deaths were reported globally in the same year. Breast cancer is considered the most prevalent cancer across the globe. This drives the need of companion diagnostics. According to GLOBOCAN data, globally, new lung cancer accounted to 2.2 million of total cancer cases in 2021. Hence, increase in incidence of cancer across the globe is projected to drive the need of companion diagnostics during the forecast period.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The companion diagnostics market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2028, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2028 along with market size estimations.

Regional Overview: Companion Diagnostics Market

  • North America accounted for the largest share of the global companion diagnostics market in 2020 and the trend is projected to continue during the forecast period. Technological advancements, increase in patient population, and rise in prevalence & incidence rate of cancer are anticipated to drive the market in the region during the forecast period. According to National Cancer statistics, 1,806,590 new cancer cases were diagnosed in the U.S. in 2020, and 606,520 people succumbed to the disease. This is expected to propel the need of companion diagnostics in North America.
  • The market in Asia Pacific is likely to grow at a rapid pace in the next few years, owing to rise in prevalence and incidence rates of cancer in several countries, outbreak of COVID-19 pandemic, and innovation & growth in advanced diagnostic products. Increase in cases of breast cancer is projected to drive the companion diagnostics market in the region. Surge in demand for personalized medicines is anticipated to propel the market in Asia Pacific. Untapped potential, several avenues of scientific research, positive economic growth, ever-increasing population, and positive regulatory scenario for healthcare in high growth countries attract leading global players to the region.

Major Players

  • The companion diagnostics market report concludes with the company profiles section, which includes key information about major players in the global companion diagnostics market
  • Leading players analyzed in the report include
    • Labcorp Drug Development
    • Agilent Technologies
    • Myriad Genetic Laboratories, Inc.
    • Qiagen
    • Roche Molecular Systems, Inc.
    • Dako, Inc.
    • Abbott
    • Foundation Medicine, Inc.
    • MolecularMD Corporation
    • Ventana Medical Systems, Inc.
    • Illumina, Inc.
    • Life Technologies Corporation
    • Invivoscribe Technologies, Inc.
    • ARUP Laboratories, Inc.
    • Leica Biosystems
    • Biogenex Laboratories, Inc.
    • bioMérieux, Inc.
    • GE Healthcare
    • Agendia N.V
    • Exact Sciences Corp
    • Genomic Health
  • Each of these players has been profiled in the companion diagnostics market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Companion Diagnostics Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 5.24 Bn

Market Forecast Value in 2028

US$ 9.30 Bn

Growth Rate (CAGR)

9%

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross-segment and regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Indication
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Melanoma
    • Others (HIV, Thalassemia)

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Labcorp Drug Development
  • Agilent Technologies
  • Myriad Genetic Laboratories, Inc.
  • Qiagen
  • Roche Molecular Systems, Inc.
  • Dako, Inc.
  • Abbott
  • Foundation Medicine, Inc.
  • MolecularMD Corporation
  • Ventana Medical Systems, Inc.
  • Illumina, Inc.
  • Life Technologies Corporation
  • Invivoscribe Technologies, Inc.
  • ARUP Laboratories, Inc.
  • Leica Biosystems
  • Biogenex Laboratories, Inc.
  • bioMérieux, Inc.
  • GE Healthcare
  • Agendia N.V
  • Exact Sciences Corp
  • Genomic Health

Customization Scope

Available upon request

Pricing

Available upon request

Companion Diagnostics Market – Segmentation

Indication
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Others (HIV, Thalassemia)
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Companion Diagnostics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of companion diagnostics market?

Companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2028

What is the anticipated CAGR of the companion diagnostics market in the forecast period?

Companion diagnostics market is estimated to expand at a CAGR of 9% from 2021 to 2028

What are the key driving factors for the growth of the companion diagnostics market?

Companion diagnostics market is driven by increase in demand and development of personalized medicine

Which is the rising prominent segment in the companion diagnostics market?

The breast cancer segment accounted for the largest market share in 2020 and the trend is expected to continue during the forecast period.

Who are the key players in the global companion diagnostics market?

Key players operating in the market are Labcorp Drug Development, Agilent Technologies, Myriad Genetic Laboratories, Inc., Qiagen, Roche Molecular Systems, Inc., Dako, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Companion Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Companion Diagnostics Market Analysis and Forecast, 2017–2028

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Recent Approval of Companion Diagnostics for Cancer Care

    5.2. Disease Prevalence & Incidence rate of Cancer

    5.3. Key Mergers & Acquisitions

    5.4. Regulatory Scenarios across globe

    5.5. Overview of Personalized Medicine

    5.6. Porters Five Forces Analysis

    5.7. COVID-19 pandemic impact on the Global Companion Diagnostics Market

6. Global Companion Diagnostics Market Analysis and Forecast, by Indication

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017–2028

        6.3.1. Breast Cancer

        6.3.2. Lung Cancer

        6.3.3. Colorectal Cancer

        6.3.4. Gastric Cancer

        6.3.5. Melanoma

        6.3.6. Others (HIV, Thalassemia)

    6.4. Market Attractiveness Analysis, by Type

7. Global Companion Diagnostics Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Companion Diagnostics Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast, by Type, 2017–2028

        8.2.1. Breast Cancer

        8.2.2. Lung Cancer

        8.2.3. Colorectal Cancer

        8.2.4. Gastric Cancer

        8.2.5. Melanoma

        8.2.6. Others (HIV, Thalassemia)

    8.3. Market Value Forecast, by Country, 2017–2028

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Indication

        8.4.2. By Country

9. Europe Companion Diagnostics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Type, 2017–2028

        9.2.1. Breast Cancer

        9.2.2. Lung Cancer

        9.2.3. Colorectal Cancer

        9.2.4. Gastric Cancer

        9.2.5. Melanoma

        9.2.6. Others (HIV, Thalassemia)

    9.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Indication

        9.4.2. By Country/Sub-region

10. Asia Pacific Companion Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017–2028

        10.2.1. Breast Cancer

        10.2.2. Lung Cancer

        10.2.3. Colorectal Cancer

        10.2.4. Gastric Cancer

        10.2.5. Melanoma

        10.2.6. Others (HIV, Thalassemia)

    10.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        10.3.1. Japan

        10.3.2. China

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Indication

        10.4.2. By Country/Sub-region

11. Latin America Companion Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2028

        11.2.1. Breast Cancer

        11.2.2. Lung Cancer

        11.2.3. Colorectal Cancer

        11.2.4. Gastric Cancer

        11.2.5. Melanoma

        11.2.6. Others (HIV, Thalassemia)

    11.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Indication

        11.4.2. By Country/Sub-region

12. Middle East & Africa Companion Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2028

        12.2.1. Breast Cancer

        12.2.2. Lung Cancer

        12.2.3. Colorectal Cancer

        12.2.4. Gastric Cancer

        12.2.5. Melanoma

        12.2.6. Others (HIV, Thalassemia)

    12.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Indication

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Market Player - Competition Matrix (by tier and size of companies)

    13.2. Market Share Analysis, by Company, 2020

    13.3. Company Profiles

        13.3.1. Labcorp Drug Development

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Financial Overview

            13.3.1.3. Product Portfolio

            13.3.1.4. Strategic Overview

            13.3.1.5. SWOT Analysis

        13.3.2. Agilent Technologies

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Financial Overview

            13.3.2.3. Product Portfolio

            13.3.2.4. Strategic Overview

            13.3.2.5. SWOT Analysis

        13.3.3. Myriad Genetic Laboratories, Inc.

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Financial Overview

            13.3.3.3. Product Portfolio

            13.3.3.4. Strategic Overview

            13.3.3.5. SWOT Analysis

        13.3.4. Qiagen

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Financial Overview

            13.3.4.3. Product Portfolio

            13.3.4.4. Strategic Overview

            13.3.4.5. SWOT Analysis

        13.3.5. Roche Molecular Systems, Inc.

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Financial Overview

            13.3.5.3. Product Portfolio

            13.3.5.4. Strategic Overview

            13.3.5.5. SWOT Analysis

        13.3.6. Dako Inc.

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Financial Overview

            13.3.6.3. Product Portfolio

            13.3.6.4. Strategic Overview

            13.3.6.5. SWOT Analysis

        13.3.7. Abbott

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Financial Overview

            13.3.7.3. Product Portfolio

            13.3.7.4. Strategic Overview

            13.3.7.5. SWOT Analysis

        13.3.8. Foundation Medicine, Inc.

            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.8.2. Financial Overview

            13.3.8.3. Product Portfolio

            13.3.8.4. Strategic Overview

            13.3.8.5. SWOT Analysis

        13.3.9. MolecularMD Corporation

            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.9.2. Financial Overview

            13.3.9.3. Product Portfolio

            13.3.9.4. Strategic Overview

            13.3.9.5. SWOT Analysis

        13.3.10. Ventana Medical Systems, Inc.

            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.10.2. Product Portfolio

            13.3.10.3. Strategic Overview

        13.3.11. Illumina, Inc.

            13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.11.2. Product Portfolio

            13.3.11.3. Strategic Overview

            13.3.11.4. SWOT Analysis

        13.3.12. Life Technologies Corporation

            13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.12.2. Product Portfolio

            13.3.12.3. Strategic Overview

            13.3.12.4. SWOT Analysis

        13.3.13. Invivoscribe Technologies, Inc.

            13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.13.2. Product Portfolio

            13.3.13.3. Strategic Overview

            13.3.13.4. SWOT Analysis

        13.3.14. ARUP Laboratories, Inc.

            13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.14.2. Product Portfolio

            13.3.14.3. Strategic Overview

            13.3.14.4. SWOT Analysis

        13.3.15. Leica Biosystems

            13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.15.2. Product Portfolio

            13.3.15.3. Strategic Overview

            13.3.15.4. SWOT Analysis

        13.3.16. Biogenex Laboratories, Inc.

            13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.16.2. Product Portfolio

            13.3.16.3. Strategic Overview

            13.3.16.4. SWOT Analysis

        13.3.17. bioMérieux, Inc.

            13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.17.2. Product Portfolio

            13.3.17.3. Strategic Overview

            13.3.17.4. SWOT Analysis

        13.3.18. GE Healthcare

            13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.18.2. Product Portfolio

            13.3.18.3. Strategic Overview

            13.3.18.4. SWOT Analysis

        13.3.19. Agendia N.V

            13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.19.2. Product Portfolio

            13.3.19.3. Strategic Overview

            13.3.19.4. SWOT Analysis

        13.3.20. Exact Sciences Corp

            13.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.20.2. Product Portfolio

            13.3.20.3. Strategic Overview

            13.3.20.4. SWOT Analysis

        13.3.21. Genomic Health

            13.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.21.2. Product Portfolio

            13.3.21.3. Strategic Overview

            13.3.21.4. SWOT Analysis

List of Tables

Table 01: Global Companion Diagnostics Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 02: Global Companion Diagnostics Value (US$ Mn) Forecast, by Region, 2017–2028

Table 03: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 04: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2028

Table 05: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 06: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 07: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 08: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 09: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 10: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 11: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028

Table 12: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

List of Figures

Figure 01: Global Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 02: Global Companion Diagnostics Market Value Share, by Indication, 2020

Figure 03: Global Companion Diagnostics Market Value Share, by Region, 2020

Figure 04: Global Companion Diagnostics Value Share Analysis, by Indication, 2020 and 2028

Figure 05: Global Companion Diagnostics Attractiveness Analysis, by Indication, 2021–2028

Figure 06: Global Companion Diagnostics Market Value (US$ Mn), by Breast Cancer, 2017–2028

Figure 07: Global Companion Diagnostics Market Value (US$ Mn), by Lung Cancer, 2017–2028

Figure 08: Global Companion Diagnostics Market Value (US$ Mn), by Colorectal Cancer, 2017–2028

Figure 09: Global Companion Diagnostics Market Value (US$ Mn), by Gastric Cancer, 2017–2028

Figure 10: Global Companion Diagnostics Market Value (US$ Mn), by Melanoma, 2017–2028

Figure 11: Global Companion Diagnostics Market Value (US$ Mn), by Others, 2017–2028

Figure 12: Global Companion Diagnostics Value Share Analysis, by Region, 2020 and 2028

Figure 13: Global Companion Diagnostics Attractiveness Analysis, by Region, 2021–2028

Figure 14: Global Companion Diagnostics Market Value (US$ Mn), by North America, 2017–2028

Figure 15: Global Companion Diagnostics Market Value (US$ Mn), by Europe, 2017–2028

Figure 16: Global Companion Diagnostics Market Value (US$ Mn), by Asia Pacific, 2017–2028

Figure 17: Global Companion Diagnostics Market Value (US$ Mn), by Latin America, 2017–2028

Figure 18: Global Companion Diagnostics Market Value (US$ Mn), by Middle East & Africa, 2017–2028

Figure 19: North America Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 20: North America Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 21: North America Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021–2028

Figure 22: North America Companion Diagnostics Value Share Analysis, by Country, 2020 and 2028

Figure 23: North America Companion Diagnostics Attractiveness Analysis, by Country, 2021–2028

Figure 24: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 25: Europe Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 26: Europe Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021–2028

Figure 27: Europe Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 28: Europe Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021–2028

Figure 29: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 30: Asia Pacific Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 31: Asia Pacific Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021–2028

Figure 32: Asia Pacific Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 33: Asia Pacific Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021–2028

Figure 34: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 35: Latin America Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 36: Latin America Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021–2028

Figure 37: Latin America Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 38: Latin America Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021–2028

Figure 39: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, 2017–2028

Figure 40: Middle East & Africa Companion Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 41: Middle East & Africa Companion Diagnostics Market Attractiveness Analysis, by Indication, 2021–2028

Figure 42: Middle East & Africa Companion Diagnostics Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 43: Middle East & Africa Companion Diagnostics Attractiveness Analysis, by Country/ Sub-region, 2021–2028

Figure 44: Global Companion Diagnostics Market Share Analysis, by Company, 2020

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

439

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved